Palomino Laboratories (PALX) Liabilities and Shareholders Equity (2022 - 2025)

Palomino Laboratories has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $8.4 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 6006.17% year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at $16.8 million (up 11949.68% YoY), while the FY2025 annual figure was $8.4 million, up 6006.17% from the prior year.
• Liabilities and Shareholders Equity came in at $8.4 million for Q4 2025 at Palomino Laboratories, up from $8.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.4 million in Q4 2025 to a low of $322.0 in Q2 2024.
• Average Liabilities and Shareholders Equity over 4 years is $1.5 million, with a median of $500.0 recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity declined 24.0% in 2023 and jumped 2581502.8% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $500.0 in 2022, then decreased by 24.0% to $380.0 in 2023, then jumped by 36248.68% to $138125.0 in 2024, then jumped by 6006.17% to $8.4 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $8.4 million in Q4 2025, $8.3 million in Q3 2025, and $1887.0 in Q2 2025.